BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang W, Cheng JW, Qin JJ, Hu B, Li X, Nijampatnam B, Velu SE, Fan J, Yang XR, Zhang R. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Lett 2019;459:156-67. [PMID: 31181320 DOI: 10.1016/j.canlet.2019.114429] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhao Q, Xiong S, Chen C, Zhu H, Xie X, Peng C, He G, Han B. Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity. Front Oncol 2022;12:972372. [DOI: 10.3389/fonc.2022.972372] [Reference Citation Analysis]
2 Terrell JR, Tang S, Faniyi OO, Jeong IH, Yin J, Nijampatnam B, Velu SE, Wang W, Zhang R, Luo M. Structural studies of antitumor compounds that target the RING domain of MDM2. Protein Science 2022;31. [DOI: 10.1002/pro.4367] [Reference Citation Analysis]
3 Lv D, Xia J, Guan X, Lai Q, Zhang B, Lin J, Shao Z, Luo S, Zhangsun D, Qin J, Wang W. Indole Diketopiperazine Alkaloids Isolated From the Marine-Derived Fungus Aspergillus chevalieri MCCC M23426. Front Microbiol 2022;13:950857. [DOI: 10.3389/fmicb.2022.950857] [Reference Citation Analysis]
4 Hong X, Guan X, Lai Q, Yu D, Chen Z, Fu X, Zhang B, Chen C, Shao Z, Xia J, Qin JJ, Wang W. Characterization of a bioactive meroterpenoid isolated from the marine-derived fungus Talaromyces sp. Appl Microbiol Biotechnol 2022. [PMID: 35416486 DOI: 10.1007/s00253-022-11914-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yu D, Qi S, Guan X, Yu W, Yu X, Cai M, Li Q, Wang W, Zhang W, Qin JJ. Inhibition of STAT3 Signaling Pathway by Terphenyllin Suppresses Growth and Metastasis of Gastric Cancer. Front Pharmacol 2022;13:870367. [PMID: 35401187 DOI: 10.3389/fphar.2022.870367] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Qi S, Guan X, Zhang J, Yu D, Yu X, Li Q, Yin W, Cheng XD, Zhang W, Qin JJ. Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis. Mol Cancer 2022;21:70. [PMID: 35272681 DOI: 10.1186/s12943-022-01538-4] [Reference Citation Analysis]
7 Kung C, Weber JD. It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy. Front Cell Dev Biol 2022;10:818744. [DOI: 10.3389/fcell.2022.818744] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Bailly C, Vergoten G. Japonicone A and related dimeric sesquiterpene lactones: molecular targets and mechanisms of anticancer activity. Inflamm Res 2022. [PMID: 35034149 DOI: 10.1007/s00011-021-01538-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wang S, Wang SQ, Teng QX, Lei ZN, Chen ZS, Chen XB, Liu HM, Yu B. Discovery of the Triazolo[1,5-a]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance. J Med Chem 2021;64:16187-204. [PMID: 34723530 DOI: 10.1021/acs.jmedchem.1c01498] [Reference Citation Analysis]
10 Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Farahani MV, Hushmandi K, Zarrabi A, Goldman A, Ashrafizadeh M, Orive G. Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discov Today 2021:S1359-6446(21)00428-1. [PMID: 34624510 DOI: 10.1016/j.drudis.2021.09.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 18.0] [Reference Citation Analysis]
11 Catherinet C, Passaro D, Gachet S, Medyouf H, Reynaud A, Lasgi C, Ghysdael J, Tran Quang C. NFAT transcription factors are essential and redundant actors for leukemia initiating potential in T-cell acute lymphoblastic leukemia. PLoS One 2021;16:e0254184. [PMID: 34234374 DOI: 10.1371/journal.pone.0254184] [Reference Citation Analysis]
12 Yu D, Xu Z, Cheng X, Qin J. The role of miRNAs in MDMX-p53 interplay. J Evid Based Med 2021;14:152-60. [PMID: 33988919 DOI: 10.1111/jebm.12428] [Reference Citation Analysis]
13 Qi SM, Dong J, Xu ZY, Cheng XD, Zhang WD, Qin JJ. PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy. Front Pharmacol 2021;12:692574. [PMID: 34025443 DOI: 10.3389/fphar.2021.692574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zhang R. Meet Our Editorial Board Member. ACAMC 2021;21:937-937. [DOI: 10.2174/187152062108210128101743] [Reference Citation Analysis]
15 Klein AM, de Queiroz RM, Venkatesh D, Prives C. The roles and regulation of MDM2 and MDMX: it is not just about p53. Genes Dev 2021;35:575-601. [PMID: 33888565 DOI: 10.1101/gad.347872.120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Desai C, Thomason J, Kohlmeyer JL, Reisetter AC, Ahirwar P, Jahanseir K, Leidinger M, Ofori-Amanfo G, Fritchie K, Velu SE, Breheny P, Quelle DE, Tanas MR. Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas. Oncotarget 2021;12:740-55. [PMID: 33889298 DOI: 10.18632/oncotarget.27928] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Xu B, Yuan L, Hu Y, Xu Z, Qin JJ, Cheng XD. Synthesis, Characterization, Cellular Uptake, and In Vitro Anticancer Activity of Fullerenol-Doxorubicin Conjugates. Front Pharmacol 2020;11:598155. [PMID: 33568999 DOI: 10.3389/fphar.2020.598155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wang W, Wang X, Rajaei M, Youn JY, Zafar A, Deokar H, Buolamwini JK, Yang J, Foster JH, Zhou J, Zhang R. Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action. Cancers (Basel) 2020;12:E3651. [PMID: 33291373 DOI: 10.3390/cancers12123651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Aburjania Z, Whitt JD, Jang S, Nadkarni DH, Chen H, Rose JB, Velu SE, Jaskula-Sztul R. Synthetic Makaluvamine Analogs Decrease c-Kit Expression and Are Cytotoxic to Neuroendocrine Tumor Cells. Molecules 2020;25:E4940. [PMID: 33114525 DOI: 10.3390/molecules25214940] [Reference Citation Analysis]
20 Zafar A, Wang W, Liu G, Xian W, McKeon F, Zhou J, Zhang R. Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope. Cancer Lett 2021;496:16-29. [PMID: 33007410 DOI: 10.1016/j.canlet.2020.09.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Li J, Liu N, Tang L, Yan B, Chen X, Zhang J, Peng C. The relationship between TRAF6 and tumors. Cancer Cell Int 2020;20:429. [PMID: 32905356 DOI: 10.1186/s12935-020-01517-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Liu G, Shi A, Wang N, Li M, He X, Yin C, Tu Q, Shen X, Tao Y, Wang Q, Yin H. Polyphenolic Proanthocyanidin-B2 suppresses proliferation of liver cancer cells and hepatocellular carcinogenesis through directly binding and inhibiting AKT activity. Redox Biol 2020;37:101701. [PMID: 32863234 DOI: 10.1016/j.redox.2020.101701] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
23 Cao H, Chen X, Wang Z, Wang L, Xia Q, Zhang W. The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation. Cell Death Discov 2020;6:53. [PMID: 32595984 DOI: 10.1038/s41420-020-0287-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
24 Wang W, Yang J, Liao Y, Cheng G, Chen J, Mo S, Yuan L, Cheng X, Qin J, Shao Z. Aspeterreurone A, a Cytotoxic Dihydrobenzofuran–Phenyl Acrylate Hybrid from the Deep-Sea-Derived Fungus Aspergillus terreus CC-S06-18. J Nat Prod 2020;83:1998-2003. [DOI: 10.1021/acs.jnatprod.0c00189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
25 Wang W, Zafar A, Rajaei M, Zhang R. Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy. Cells 2020;9:E1176. [PMID: 32397368 DOI: 10.3390/cells9051176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Zhang J, Wang W, Zhou Y, Yang J, Xu J, Xu Z, Xu B, Yan L, Cheng XD, Li M, Qin JJ. Terphenyllin Suppresses Orthotopic Pancreatic Tumor Growth and Prevents Metastasis in Mice. Front Pharmacol 2020;11:457. [PMID: 32322210 DOI: 10.3389/fphar.2020.00457] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
27 Qi SM, Cheng G, Cheng XD, Xu Z, Xu B, Zhang WD, Qin JJ. Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet? Front Cell Dev Biol 2020;8:233. [PMID: 32300595 DOI: 10.3389/fcell.2020.00233] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
28 Dong J, Qin Z, Zhang WD, Cheng G, Yehuda AG, Ashby CR Jr, Chen ZS, Cheng XD, Qin JJ. Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update. Drug Resist Updat 2020;49:100681. [PMID: 32014648 DOI: 10.1016/j.drup.2020.100681] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 29.0] [Reference Citation Analysis]
29 Wang W, Qin JJ, Rajaei M, Li X, Yu X, Hunt C, Zhang R. Targeting MDM2 for novel molecular therapy: Beyond oncology. Med Res Rev 2020;40:856-80. [PMID: 31587329 DOI: 10.1002/med.21637] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]